210 related articles for article (PubMed ID: 32842835)
1. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
[TBL] [Abstract][Full Text] [Related]
2. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
3. Predicting long-term trends in inflammatory neuropathy outcome measures using latent class modelling.
Keh RYS; Selby DA; Jones S; Gosal D; Lavin T; Lilleker JB; Carr AS; Lunn MP
J Peripher Nerv Syst; 2022 Mar; 27(1):84-93. PubMed ID: 34936164
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
Racosta JM; Sposato LA; Kimpinski K
Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
[TBL] [Abstract][Full Text] [Related]
5. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
[TBL] [Abstract][Full Text] [Related]
7. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
Dalakas MC
J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
[TBL] [Abstract][Full Text] [Related]
9. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.
Lucke IM; Adrichem ME; Wieske L; van der Kooi AJ; Verhamme C; van Schaik IN; Eftimov F
J Neurol Sci; 2019 Feb; 397():141-145. PubMed ID: 30623818
[TBL] [Abstract][Full Text] [Related]
11. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.
Kokubun N; Sada T; Yuki N; Okabe M; Hirata K
Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
13. Update on therapy of chronic immune-mediated neuropathies.
Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E
Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
15. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
16. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
Hughes RA
Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines?
Rosier C; Graveline N; Lacour A; Antoine JC; Camdessanché JP
Eur J Neurol; 2019 Apr; 26(4):575-580. PubMed ID: 30326184
[TBL] [Abstract][Full Text] [Related]
18. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
19. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Gallia F; Balducci C; Nobile-Orazio E
J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
